SINOMAB BIOSCIENCE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.9 HKD | 0.00% |
|
+0.53% | +13.10% |
| 03-25 | SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-07 | SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director | CI |
| Sales 2021 | 26.66 208.68 36.44 | Sales 2022 | 4.03 31.56 5.51 | Capitalization | 1.65B 12.95B 2.26B |
|---|---|---|---|---|---|
| Net income 2021 | -288M -2.25B -394M | Net income 2022 | -284M -2.22B -388M | EV / Sales 2021 | 76,183,773 x |
| Net cash position 2021 | 314M 2.46B 429M | Net cash position 2022 | 65.2M 510M 89.12M | EV / Sales 2022 | 394,141,340 x |
| P/E ratio 2021 |
-8.04
x | P/E ratio 2022 |
-5.58
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 37.76% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +0.53% | ||
| Current month | +21.79% | ||
| 1 month | +31.03% | ||
| 3 months | +20.25% | ||
| 6 months | +75.93% | ||
| Current year | +13.10% |
1 week
1.80
1.95
1 month
1.461.95
Current year
1.271.95
1 year
1.031.95
3 years
0.833.89
5 years
0.837.30
10 years
0.837.30
| Managers | Title | Age | Since |
|---|---|---|---|
Shui On Leung
CEO | Chief Executive Officer | 64 | 01-04-26 |
Jian Ping Hua
DFI | Director of Finance/CFO | 42 | 18-12-31 |
Li Xin Zhang
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dylan Tinker
BRD | Director/Board Member | 55 | 19-10-30 |
Ping Cho Hon
BRD | Director/Board Member | 64 | 19-10-30 |
Hai Gang Chen
BRD | Director/Board Member | 41 | 17-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.9 | 0.00% | 73,200 |
| 24-04-25 | 1.9 | 0.00% | 35,400 |
| 24-04-24 | 1.9 | 0.00% | 77,400 |
| 24-04-23 | 1.9 | -1.55% | 82,200 |
| 24-04-22 | 1.93 | +2.12% | 42,900 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am
More quotes
SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The Companyâs product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogrenâs syndrome (SS) and other immunological diseases.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.10% | 265M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 3681 Stock
